Skip to content

Study of the effect of HMB on sarcopenia in the community-dwelling elderly

Study of the effect of HMB on sarcopenia in the community-dwelling elderly

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012826
Enrollment
Unknown
Registered
2017-09-27
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

HMB+ONS:health education, and HMB3g and ONS 568Kcal, daily
ONS:oral nutritional supplementation 568kcal/d AND health education

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medical Scientices
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. The elderly subjects over the age of 65 years were willing to exercise according to the study protocol and signed informed consent; 2. The subjects who are living in the community and are not home-bound; 3. And with impaired muscular function according to the modified criteria of Asian Sarcopenia Working Group, the modified usual gait speed of <1.0 m / s or grip strength reduction (male <26Kg, female <18Kg), then further screening of muscle mass: with BIA muscle volume <7.0 kg/m2, women <5.7 kg/m2 diagnosis Less disease; 4. And with stable health condition and abnormal nutritional assessment score by MNA-SF(=11); 5. And could take the nutritional supplement by oral.

Exclusion criteria

Exclusion criteria: 1) had acute disease or acute complication of chronic disease; 2) less than 6 weeks after a large operation or with planned operation in the coming 3 months; 3) having an active malignant disease; 4) have severe chronic disease, such as severe cardiopulmonary disease patients (NYHA=3),neurological disease(immobility, moderate or severe dementia), active or severe liver disease, severe kidney disease (e-GFR11.1mmol/L, or HbA1c > 8%; 7) Any conditions that the investigator or doctor do not think suitable in this study; 8) Being allergic or intolerable to any compositions of the oral nutritional supplementation; 9) Being enrolled in any other clinical trial.

Design outcomes

Primary

MeasureTime frame
muscle mass;handgrip Strength;short physical performance battery;

Countries

China

Contacts

Public ContactLiu Xiaohong, Wang Qiumei

Peking Union Medical College Hospital, Chinese Academy of Medical Scientices

qiumei_wang@163.com+86 18610003310, 18600016946

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026